Quick Summary
- First quarter adjusted EPS came in at $0.99 versus analyst expectations of $1.05
- Company lowered full-year EPS outlook to $4.80–$5.00 from previous $4.95–$5.15 range
- Quarterly revenue reached $5.13 billion, surpassing the $5.03 billion consensus
- Shares declined approximately 9% during premarket hours
- Major reorganization announced: merging top two divisions into $14.6 billion business unit
Shares of GE HealthCare tumbled in Wednesday’s premarket session after the medical imaging and diagnostics company delivered disappointing first-quarter earnings and reduced its profit forecast for the full year.
The healthcare technology firm reported adjusted earnings of $0.99 per share for the first quarter, falling short of analyst projections of $1.05. However, the top-line performance painted a brighter picture — quarterly revenues totaled $5.13 billion, representing a 7.4% year-over-year increase and exceeding the Street’s expectation of $5.03 billion.
Operating margins came in at 13.5%, roughly one percentage point below what analysts had anticipated.
Premarket trading saw GEHC shares plummet approximately 9.6% to around $61.93, compounding what has already been a challenging year. The stock had declined 16% year-to-date before Wednesday’s session.
GE HealthCare Technologies Inc., GEHC
Chief Executive Peter Arduini attributed the reduced guidance primarily to escalating cost pressures. The company faced higher expenses across multiple categories during the quarter, including memory chip components, petroleum-based products, and transportation services. Arduini indicated that management anticipates mitigating over 50% of these inflationary impacts through a combination of strategic pricing adjustments and internal cost-reduction initiatives.
The company revised its full-year adjusted earnings guidance downward to a range of $4.80–$5.00 per share, compared to its previous forecast of $4.95–$5.15. Wall Street analysts had been modeling $5.06. Despite the profit outlook reduction, GE HealthCare maintained its organic revenue growth projection of 3% to 4%.
First-quarter orders increased 1.1%, while comparable sales advanced 2.9%.
Major Organizational Overhaul
In a significant strategic move, GE HealthCare revealed plans to consolidate its two largest business divisions — imaging and advanced visualization solutions — into a unified segment named Advanced Imaging Solutions, which will command a combined revenue base of approximately $14.6 billion.
Phil Rackliffe, who previously oversaw the advanced visualization solutions division, has been appointed to lead the newly formed combined segment. Roland Rott, the former imaging division head, will depart from the organization.
Management characterized the restructuring as a strategic initiative aimed at developing a more integrated imaging platform while driving operational synergies across the business.
Additionally, Catherine Estrampes, a veteran executive with 35 years at the company, was promoted to Chief Commercial and Growth Officer. In this newly established role, she will oversee a global markets region encompassing all territories outside China.
Underperforming Among GE Spinoffs
GE HealthCare has delivered the most disappointing returns among the trio of companies created from the breakup of the original General Electric conglomerate. Since separating from the parent company in January 2023, GEHC shares have appreciated only approximately 13%, underperforming the S&P 500 by more than 70 percentage points during that timeframe.
In stark contrast, GE Aerospace has soared over 110% since the GE split was completed in April 2024. GE Vernova has been the exceptional performer, skyrocketing more than 675% over the identical period.
GE Aerospace has capitalized on robust aircraft engine demand cycles. GE Vernova has benefited significantly from the surge in power infrastructure investment. Meanwhile, GE HealthCare has navigated a more challenging operating landscape characterized by tepid demand conditions, tariff-related headwinds, and ongoing inflationary pressures.
The medical equipment manufacturer does enter 2026 with a record order backlog approaching $22 billion, which executives have highlighted as a crucial foundation supporting anticipated growth acceleration.
Prior to Wednesday’s earnings announcement, GEHC stock had gained merely 1% over the trailing twelve-month period.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
